Chimeric Antigen Receptor News and Research

RSS

Duke-NUS team develops test to monitor engineered T cells in cancer treatment

A novel test developed by Duke-NUS researchers enables real-time monitoring of T cells that have been engineered to fight cancer, after re-introduction into the body of a cancer patient.

15 Nov 2024

Customizable biological sensors activate cancer immunotherapy only in tumor environments

Most cancer treatments – from chemotherapies to engineered immune cells – have a host of side effects, in large part because they affect healthy cells in the body at the same time as targeting tumor cells.

15 Nov 2024

CAR T cell therapy breakthroughs bring new hope for treating solid tumors

Researchers advance CAR T cell therapy for solid tumors by innovating ways to overcome the unique barriers of solid tumor environments, with promising clinical results.

13 Nov 2024

MD Anderson launches new institute for advancing cell therapy

The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & Innovation, which will build upon longstanding MD Anderson clinical and research expertise to lead the world in developing and advancing impactful cell therapies for patients in need.

8 Nov 2024

Modulating CD39 expression to enhance CAR-T cell therapy against hepatocellular carcinoma

In the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma (HCC), a recent study has identified a pivotal role for CD39 expression in modulating the function of CAR-T cells.

5 Nov 2024

Researchers identify mechanism of immune suppression in ovarian cancer

Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack—blocking the energy supply T cells depend on. The study, published Oct. 23 in Nature, points toward a promising new immunotherapy approach for ovarian cancer, which is notoriously aggressive and hard to treat.

24 Oct 2024

Researchers discover how ovarian tumors cripple immune cells

Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack - blocking the energy supply T cells depend on.

23 Oct 2024

New CAR T cells offer controlled treatment for solid tumors

Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells - a type of cancer immunotherapy - that can be switched on to varying degrees of intensity and then switched off on demand with existing drugs.

21 Oct 2024

Scientists reveal how miRNAs shape cancer and offer new paths for treatment

Review explores how microRNAs (miRNAs) interact in cancer development, their potential in diagnosis, and innovative therapeutic strategies, including overcoming chemotherapy resistance.

20 Oct 2024

UCLA and Parker Institute renew alliance to advance cancer immunotherapy

UCLA and the Parker Institute for Cancer Immunotherapy (PICI) have renewed their alliance to advance research in cancer immunotherapy and accelerate the development of curative treatments for the most difficult-to-treat cancers.

16 Oct 2024

Innovative immunotherapy harnesses natural killer T cells to combat solid tumors

In the fight against cancer, chimeric antigen receptor T cell (CAR-T) therapy has achieved notable success in treating blood cancers. However, it has been largely ineffective against solid tumors.

7 Oct 2024

New cell therapy offers effective treatment for patients with T-cell acute lymphoblastic leukemia

A new cell therapy, targeting CD7 on leukaemia cells, gives a potentially effective treatment for patients with T-cell acute lymphoblastic leukaemia (T-ALL) who have exhausted all standard treatment options.

7 Oct 2024

Outpatient CAR-T therapy shows promise for treating lymphoma patients

In the largest prospective study to date examining the use of chimeric antigen receptor (CAR)-T therapy in a community setting on an outpatient basis, patients with relapsed or refractory large B-cell lymphoma (LBCL) responded well to treatment with few serious side effects, according to results published today in Blood Advances.

30 Sep 2024

Researchers identify a protein that recharges T cells for long-lasting cancer remission

Research shows Fc–IL-4 revitalizes exhausted CD8+ T cells, boosting antitumor responses and highlighting the potential of combining type 1 and type 2 immunity.

30 Sep 2024

Study reveals positive correlation between type 2 immunity and long-term cancer remission

Results from a preclinical study in mice, led by EPFL, and a collaborative clinical study in patients show that the type 2 immune response – associated with parasitic infection and thought to play a negative role in cancer immunity – is positively correlated with long-term cancer remission.

26 Sep 2024

New discovery offers hope for overcoming CAR-T cell therapy resistance

Mayo Clinic researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients.

12 Sep 2024

New insights into stiff-person syndrome, advancing diagnosis and treatment

Research explores the complexities of diagnosing and treating stiff-person syndrome, emphasizing the uncertain role of GAD antibodies and the promise of novel therapies.

5 Sep 2024

Advances in precision medicine enhance cancer immunotherapy

The field of precision medicine, especially in the context of cancer immunotherapy, has seen significant advancements in recent years.

20 Aug 2024

New project aims to study the combination of two therapies for pediatric brain cancer

Natasha Sheybani, assistant professor of biomedical engineering at the University of Virginia School of Engineering, will collaborate with researchers at Children's National Hospital to study the combination of two therapies for pediatric brain cancer.

19 Aug 2024